2. USA IVD Market Opportunity: $35 Billion
Source: Yole Development Market Research Report (Sep, 2012)
USA Elderly Population:
40 Million aged 65 or older
88 Million aged 65 or older by 2050
USA Affordable Care Act (2014):
30 Million newly covered patients
$900 Million (2017)
3. A. Geriatrics Care: Nursing Homes & Assisted Living
B. POC Diagnostics: State of Health Panel Test
Pain Point:
Delayed Prognosis:
Slow turnaround time (12/24hrs) from Blood Samples to Results
Cost & Inconvenience:
Multiple Visits to Doctors, Specialists & Labs.
Laboratory Specialists, Complex Equipment & High CapEx.
POC Opportunity in Healthcare
4. Cytochrome (CYP) P450 Biosensor:
CYP enzymes and transporters, have profound effects on the activity and
expression and therefore also the final biological activity, efficacy and safety of
drugs.
90% of marketed drugs are metabolized by only five CYP isoforms (CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP3A4/5)
Pain Point:
Cost & Time: Currently-available methods (GC, HPLC, MS) used for in vitro
quantifying the levels of drugs in biological fluids are time-consuming, require
complex instruments and expensive ($300/patient).
Limitations: Cannot measure plasma concentrations of drugs or their metabolites
during pharmacological cure. Ex: Transplant Patients
POC Opportunity: Clinical Trials & Drug Monitoring
6. Canasita: Revenue & Business Plan
Note:
1. Assumes Tax Rate of 35%
2. COGS include licensing and royalty payments where applicable
3. R&D Costs include cost of Clinical Trials where applicable